Published online Oct 16, 2024. doi: 10.12998/wjcc.v12.i29.6262
Revised: July 2, 2024
Accepted: July 10, 2024
Published online: October 16, 2024
Processing time: 157 Days and 15.8 Hours
Clear cell sarcoma (CCS) is a rare soft-tissue sarcoma that accounts for less than 1% of all cases and was originally reported in 1965. The incidence of CCS is estimated to be approximately 0.014/100000 depending on the surveillance, epidemiology and end results databases. CCS is a highly invasive type that mainly metastasizes to the lungs, followed by the bones and brain; however, pancreatic metastasis is relatively rare. It has a high probability of recurrence or metastasis and has a poor prognosis with a high mortality rate. Finally, even after recovery, it is fundamental to keep regular postoperative follow-up for CCS patients.
Core Tip: In this editorial, we comment on a case report by Liu et al. According to the authors of this article, the objective of presenting this case was to bring to attention of metastatic clear cell sarcoma (CCS) of the pancreas. CCS is an uncommon soft-tissue sarcoma, making up less than 1% of all cases, and was first documented in 1965. The estimated incidence of CCS is around 0.014 per 100000 individuals, varying based on data from surveillance, epidemiology, and end results databases.